U.S. Healthtech Stock News

In December 2025, Masimo entered into a new unsecured credit facility comprising a US$250 million term loan and US$750 million revolving commitments, replacing its prior agreement and extending maturities to December 2030. The facility’s leverage-linked interest spreads, unused fee, and potential US$400 million accordion highlight how Masimo is reconfiguring its balance sheet to enhance financial flexibility for capital investment and working capital. We’ll now examine how Masimo’s expanded...

PROS Holdings (PRO) has quietly turned into a comeback story, with the stock up nearly 50% over the past 3 months even as its 1 year return still sits slightly negative. See our latest analysis for PROS Holdings. That sharp 90 day share price return of roughly 49% has flipped sentiment after a long grind, even though the 1 year total shareholder return of about negative 5% shows this is still an early stage comeback rather than a completed turnaround. If PROS has you rethinking growth stories...

Artivion (AORT) has quietly become a strong performer, with shares up sharply this year even after a recent pullback. Investors are starting to weigh whether the current price still reflects its growth trajectory. See our latest analysis for Artivion. The stock’s latest pullback, including a modest 1 day share price return of minus 1.17 percent to 44.07 dollars, comes after a powerful year to date share price return of 56.94 percent and a standout 3 year total shareholder return of 240.84...

Antero Resources (AR) has quietly outperformed many energy peers over the past month, with the stock up around 11% and roughly 16% over the past three months, catching the attention of value-focused investors. See our latest analysis for Antero Resources. Zooming out, that recent strength adds to a solid run, with a roughly mid teens 3 month share price return and a near 20% one year total shareholder return indicating that momentum is still building around Antero’s growth story and risk...

National Health Investors (NHI) has quietly outperformed many income names this year, and with its shares up about 15% year to date, investors are asking whether the momentum still matches the fundamentals. See our latest analysis for National Health Investors. The steady year to date share price return of around 15% to about $78.82, backed by solid recent revenue and net income growth, suggests momentum is still building rather than fading, and the market is slowly repricing National Health...

Service Corporation International (SCI) just gave investors a confidence boost, combining upbeat analyst commentary with stronger than expected third quarter results and a higher quarterly dividend that underlines management’s comfort with future cash flows. See our latest analysis for Service Corporation International. The upbeat earnings surprise and dividend hike help explain why, despite a recent 1 month share price return of negative 4.29 percent and a 1 year total shareholder return of...

CACI International (CACI) just landed two sizable multi year task orders with the U.S. Navy and Army, bolstering its backlog and strengthening already important defense relationships that support the stock’s longer term earnings power. See our latest analysis for CACI International. Those fresh Navy and Army wins come after a strong run, with the share price up sharply on a 90 day basis and multi year total shareholder returns showing steady, compounding momentum. If contract driven growth...

In early December 2025, United Natural Foods reported first-quarter sales of US$7.84 billion, a reduced net loss of US$4 million, and US$10 million in long-lived asset impairment charges, while affirming full-year guidance that includes the possibility of returning to a modest profit. Although revenue edged slightly lower year over year, the significantly smaller loss per share and maintained outlook suggest operational progress despite ongoing cost and asset challenges. We’ll now examine...

In early December 2025, Prologis’ Board declared a regular quarterly cash dividend of US$1.01 per common share and a US$1.0675 dividend on its 8.54% Series Q Cumulative Redeemable Preferred Stock, both payable on December 31, 2025, to holders of record on December 16, 2025. Alongside record leasing of nearly 62 million square feet, a growing data center pipeline, and raised operational guidance, these dividends underline how Prologis is leaning on both stable cash returns and expanding...

In recent days, Standex International was upgraded to a “buy” rating by Wall Street Zen and other analysts after the company posted earnings that exceeded estimates and delivered strong year-on-year revenue growth. This combination of analyst optimism and outperformance against expectations points to rising confidence in Standex’s execution and demand for its products across key end markets. We’ll now examine how the recent analyst upgrades, following Standex’s earnings beat, may influence...

Realty Income (O) has quietly lagged the broader market over the past 3 months, even as its fundamentals keep improving. With the share price drifting, investors are asking whether this dividend REIT now offers a better entry point. See our latest analysis for Realty Income. Over the past year, Realty Income has quietly delivered a solid positive year to date share price return while its longer term total shareholder returns have been more modest. This suggests momentum is improving but not...

In recent days, Ollie’s Bargain Outlet Holdings announced it would report Q3 2026 results before the market open on December 9, 2025, alongside continuing its long-running holiday round‑up partnership with Feeding America to support local food banks. This combination of an upcoming earnings release, upbeat analyst expectations, and a values-driven Feeding America campaign highlights how Ollie’s is leaning on both operational execution and brand goodwill to deepen customer and investor...

Mercury General (MCY) has quietly turned into a strong insurance rebound story, with the stock up about 36% year to date and roughly 18% over the past 3 months, catching value-focused investors attention. See our latest analysis for Mercury General. That 35.8% year to date share price return, alongside a 3 year total shareholder return of about 175.5%, suggests investors are steadily warming to Mercury General again as underwriting results and sentiment improve around property and auto...

Brighthouse Financial (BHF) has quietly outpaced the broader insurance space over the past year, climbing roughly 30% while still trading almost flat over the past month. This combination sets up an interesting entry point. See our latest analysis for Brighthouse Financial. Over the past year, Brighthouse Financial’s roughly 30% total shareholder return has been driven by improving earnings trends and steadier credit markets, even as its recent share price momentum has cooled near 65...

CubeSmart (CUBE) just delivered a mixed Q3 2025 update, missing slightly on earnings but topping revenue forecasts and lifting guidance again, while analysts split on what that means for growth from here. See our latest analysis for CubeSmart. The Q3 update lands after a choppy stretch, with the share price down about 11% over three months and the 1 year total shareholder return near minus 20%, suggesting momentum has cooled even as guidance and urban demand stay supportive. If CubeSmart's...

Zymeworks recently received FDA approval for its first internally developed therapy, zanidatamab, for HER2-positive biliary tract cancer, while also reporting clinical progress across its antibody-drug conjugate pipeline. This approval, alongside new supportive analyst coverage, marks a shift toward a royalty-focused, capital-light model that could reshape how investors assess Zymeworks' long-term earnings potential. Now we’ll explore how zanidatamab’s FDA approval, as Zymeworks’ first...

Coinbase Global (COIN) has been quietly recalibrating after a choppy few months, with the stock slipping about 11% over the past month and 14% over the past 3 months, even as crypto volumes remain active. See our latest analysis for Coinbase Global. Step back from the recent pullback and Coinbase still looks like a name where sentiment is resetting rather than collapsing. The stock has delivered a modest year to date share price return alongside a powerful three year total shareholder return,...

User attention on T. Rowe Price Group (TROW) is picking up again as fresh analyst commentary zeroes in on familiar headwinds, from ongoing fund outflows to fee pressure, raising questions about what actually drives upside from here. See our latest analysis for T. Rowe Price Group. Despite the cautious analyst tone and leadership changes in its Asia Pacific institutional business, T. Rowe Price Group's share price at $104.52 reflects fading momentum, with a negative year to date share price...

Earlier this year, Centessa Pharmaceuticals reported strong Phase 2 results for its sleep disorder drug ORX750, while also launching a US$250,000,000 public offering of 11.6 million American Depositary Shares and disclosing a US$300,000 insider share sale by Mario Alberto Accardi, President of the Orexin Program. The promising ORX750 data highlight Centessa’s effort to build a focused sleep-disorder franchise, even as it raises fresh capital and an insider trims holdings. We’ll now examine...

Stryker Corporation has announced that longtime executive Spencer Stiles will become President and Chief Operating Officer on January 1, 2026, while Dylan Crotty will be promoted to Group President of Orthopaedics, continuing the company’s practice of elevating leaders with deep internal experience. These leadership moves highlight Stryker’s emphasis on operational continuity and succession from within, which could influence how it executes on growth, innovation, and global expansion...

In recent weeks, Baxter International Inc. launched cash tender offers to repurchase any and all of its US$750,000,000 2.600% senior unsecured notes due 2026 and up to US$600,000,000 of its US$1.45 billion 1.915% senior unsecured notes due 2027, while also amending its five-year credit agreement to temporarily relax net leverage covenants. These balance sheet moves come as Baxter faces a wave of securities class action lawsuits tied to alleged undisclosed safety defects in its Novum LVP...

Aveanna Healthcare Holdings recently presented at the Bank of America Home Care Conference on 9 December 2025, underscoring its role in the US home care market. Analyst coverage initiated by William Blair with an Outperform rating, alongside positive commentary from other firms, has reinforced Aveanna’s positioning as a leading private duty nursing provider benefiting hospitals, payers, and families. Now, we’ll explore how this fresh Outperform initiation and endorsement of Aveanna’s home...

Wondering if Cushman & Wakefield at around $15 a share is quietly turning into a value story? This breakdown will walk you through whether the recent price actually matches the underlying business. The stock is down 8.5% over the last week and 3.3% over the last month, but it is still up 20.8% year to date and roughly flat over the last year, which suggests sentiment is shifting even if the long term chart looks more muted. Recent headlines have focused on how Cushman & Wakefield is...

In recent weeks, Western Digital has drawn investor attention as a newly focused hard disk drive pure play, reporting a 27% year-over-year revenue increase in its first quarter of fiscal 2026 amid strong AI-driven data center storage demand. At the same time, a series of insider share sales and a new analyst price target have raised questions about how leadership and external observers view the company’s prospects as AI-related storage needs accelerate. Now we’ll explore how Western...